UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported) March 7, 2005
NOVADEL
PHARMA INC.
(Exact
Name of Registrant as Specified in Its Charter)
|
Delaware |
|
001-32177 |
|
22-2407152 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File No.) |
|
(I.R.S.
Employer
Identification
No.)
|
25
Minneakoning Road
Flemington,
New Jersey 08822
(Address
of principal executive offices) (Zip Code)
(908)
782-3431
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
|
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On March
10, 2005, NovaDel Pharma Inc. (the “Company”), issued a press release to
announce that Thomas E. Bonney has been appointed to its Board of Directors,
bringing the total number of board members to seven. Mr. Bonney was appointed to
the Board on March 10, 2005, and was also appointed as chairman of the Audit
Committee. Based on Mr. Bonney’s credentials, he is financially sophisticated as
defined in Section 121(b)(2)(a)(ii) of the listing standards of the American
Stock Exchange and will serve as the audit committee financial expert as defined
in the regulations promulgated by the Securities and Exchange Commission. The
full text of the press release is set forth in Exhibit 99.1 hereto.
Item
8.01. Other
Events
On March
7, 2005, the Company issued a press release to announce that it has been issued
its fifth European patent for its proprietary lingual spray technology.
The patent covers the Company's lingual spray technology using any of the
following compounds: antihistamines, steroid hormones, non-steroidal
anti-inflammatory drugs (NSAIDS), benzodiazepines, anti-depressants, alkaloids,
hormones and narcotic analgesics. The Company owns five issued US patents and 27
patent applications pending in the United States, Canada and Europe. The full
text of the
press release is set forth in Exhibit 99.2 hereto.
Item
9.01. Financial
Statements and Exhibits.
(c) Exhibits.
| 99.1. |
Press
release dated March 10, 2005, titled “NovaDel Names Thomas Bonney C.P.A.
to Board.” |
| 99.2. |
Press
release dated March 7, 2005, titled “NovaDel Pharma Issued Fifth European
Patent for Buccal Sprays.” |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
NovaDel Pharma
Inc. |
|
|
|
|
By: |
/s/ Jean W. Frydman |
| |
Name: Jean W. Frydman |
| |
Title: Vice President and General
Counsel |
Date:
March 11, 2005
EXHIBIT
INDEX
| |
|
|
|
Exhibit |
|
Description |
|
99.1 |
|
Press
release dated March 10, 2005, titled “NovaDel Names Thomas Bonney C.P.A.
to Board.” |
|
99.2 |
|
Press
release dated March 7, 2005, titled “NovaDel Pharma Issued Fifth European
Patent for Buccal Sprays.” |